GlassScriptPhysician profile
Robert J Reichling
NPI 1144268616
$3,658.39
in general payments reported to CMS, 2019-2025
43 companies · $695 in 2025
The $695 reported for 2025 was more than what 79% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $159 · 2021: $462 · 2022: $683 · 2023: $584 · 2024: $233 · 2025: $695.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,511.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $422.61 | 2019-2022 | |
| Novo Nordisk INC | $345.91 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Glaxosmithkline, LLC. | $297.96 | 2019-2024 | Arexvy, Trelegy Ellipta, Shingrix |
| Abbvie INC. | $279.60 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $181.98 | 2021-2025 | Breztri, Farxiga, Airsupra |
| Bayer Healthcare Pharmaceuticals INC. | $171.83 | 2021-2023 | |
| Pfizer INC. | $170.99 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $155.86 | 2019-2023 | |
| Lilly USA, LLC | $130.45 | 2019-2023 | Mounjaro, Jardiance, Zepbound |
| Mylan Specialty L.P. | $125.40 | 2019-2022 | |
| Viatris Specialty LLC | $100.59 | 2025 | Yupelri |
| Takeda Pharmaceuticals U.S.A., INC. | $99.52 | 2021-2022 | |
| Verona Pharma, INC. | $97.17 | 2025 | Ohtuvayre |
| Insmed, INC. | $86.30 | 2025 | Arikayce, Brinsupri |
| Insulet Corporation | $56.22 | 2024-2025 | Omnipod |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Grifols USA, LLC | $55.04 | 2022-2025 | Prolastin-C Liquid |
| Sanofi-Aventis U.S. LLC | $54.21 | 2019-2023 | |
| Dexcom, INC. | $53.91 | 2019-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $49.23 | 2019-2023 | Repatha, Otezla |
| Abbott Laboratories | $48.69 | 2023-2025 | Eterna, Cardiomems |
| Regeneron Healthcare Solutions, INC. | $44.93 | 2025 | Dupixent |
| Boehringer Ingelheim Pharmaceuticals, INC. | $43.77 | 2019-2023 | |
| Aimmune Therapeutics, INC. | $41.12 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.74 | 2019 | |
| Merck Sharp & Dohme LLC | $39.45 | 2021-2025 | Keytruda |
| Mannkind Corporation | $39.39 | 2023 | Afrezza |
| Astellas Pharma US INC | $37.76 | 2019-2022 | |
| Ani Pharmaceuticals, INC. | $36.57 | 2025 | Purified Cortrophin Gel |
| Supernus Pharmaceuticals, INC. | $33.01 | 2019 | |
| Radius Health, INC. | $31.68 | 2019 | |
| Zealand Pharma US, INC. | $31.44 | 2020 | |
| United Therapeutics Corporation | $30.45 | 2025 | Tyvaso |
| Tandem Diabetes Care, INC. | $27.79 | 2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Olympus America INC. | $26.89 | 2019 | |
| Tonix Medicines, INC. | $25.83 | 2025 | Tonmya |
| Baxter Healthcare | $25.10 | 2024 | Hillrom - Life 2000 Ventilation System |
| Advanced Respiratory, INC | $23.01 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $20.34 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.25 | 2023 | Opsumit |
| Davol INC. | $15.49 | 2019 | |
| Corcept Therapeutics | $14.41 | 2025 | Korlym |
| Exact Sciences Corporation | $14.27 | 2025 | Cologuard Collection Kit |
| Eisai INC. | $12.23 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Reichling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.